Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06440005 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Angiex.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
6
Study locations

NCT06440005 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Angiex. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06440005, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Angiex.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
6
Study locations

Study Summary

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.

Conditions Studied

Breast Cancer Prostate Cancer Cancer Colorectal Cancer Pancreatic Cancer Advanced Cancer Liver Cancer Metastatic Solid Tumor Angiosarcoma Locally Advanced Carcinoma

Interventions

  • DRUG AGX101

Study Locations (6)

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles

Florida

  • Florida Cancer Specialist - Sarasota

Missouri

  • Washington University School of Medicine - St Louis

Tennessee

  • Sarah Cannon Research Center - Nashville

Texas

  • NEXT Oncology - San Antonio

Virginia

  • NEXT Oncology - Fairfax

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-07-22
Est. Completion 2027-09-06
Phase Phase 1

Sponsor

Angiex

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06440005

The ClinicalTrials.gov registry entry for NCT06440005 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Angiex, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AGX101 is the first listed.

NCT06440005 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Missouri.

Frequently Asked Questions

What is clinical trial NCT06440005 about?

NCT06440005 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors". AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re...

What is the current status of trial NCT06440005?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-07-22. Estimated completion is 2027-09-06.

What conditions does trial NCT06440005 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer.

What interventions are being tested in trial NCT06440005?

The interventions under investigation include: AGX101 (DRUG).

Who is sponsoring clinical trial NCT06440005?

This trial is sponsored by Angiex, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06440005 being conducted?

This trial has 6 study locations across California, Florida, Missouri, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.